Here's the latest UPC 11830 (fail-to-deliver) list of biotech stocks from the NASDAQ site:
ATLC Atlantic Pharmaceuticals, Inc.
AVGN Avigen, Inc.
BPUR Biopure Corporation
CLPA Cell Pathways, Inc.
CLTR Coulter Pharmaceutical, Inc.
CYPH Cytoclonal Pharmaceutics Inc.
DSCO Discovery Laboratories Inc.
GENXY Genset - American Depositary Receipts
GERN Geron Corporation
GLIA Gliatech Inc.
INKP Inkine Pharmaceutical Company Inc.
NEOT NeoTherapeutics, Inc.
NPSP NPS Pharmaceuticals, Inc.
VPHM ViroPharma Incorporated
ZONA Zonagen, Inc.
Nearly all of these stocks (except NEOT which is flat) have done pretty well of late. I actually own a fair proportion of them ( specifically BPUR, CLTR, GENXY, GERN, GLIA, NPSP and VPHM). I think most of them are popular (and crowded) shorts.
CLPA of course seems to have had a squeeze, and GLIA is surely on the edge of one, with its large short position and small float. Not for the faint of heart of course - expect a "nasty-rumor-of-the-day" environment.
BTW stocks on the list are automatically put on "hard to borrow" lists - they can still technically be shorted if the broker can locate specific shares to borrow.
Peter
|
